Skip to content


    DEA Class; Rx

    Common Brand Names; Mintezol

    • Anthelmintics

    Mintezol (thiabendazole) Chewable Tablets And Suspension is a prescription medicine used to treat the symptoms of anti-worm medication used to treat infections caused by worms such as Threadworm, Pinworm, Hookworm, Whipworm, Roundworm and Trichinosis. Mintezol may be used alone or with other medications.

    Mintezol belongs to a class of drugs called Anthelmintics.

    It is not known if Mintezol is safe and effective in children weighing less than 30 lbs.  

    MINTEZOL (thiabendazole) is indicated for the treatment of: Strongyloidiasis (threadworm) Cutaneous larva migrans (creeping eruption) Visceral larva migrans

    Trichinosis: Relief of symptoms and fever and a reduction of eosinophilia have followed the use of MINTEZOL (thiabendazole) during the invasion stage of the disease.

    Thiabendazole is usually inappropriate as first line therapy for enterobiasis (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients.

    MINTEZOL (thiabendazole) should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable: Uncinariasis (hookworm: Necator americanus and Ancylostoma duodenale); Trichuriasis (whipworm); Ascariasis (large roundworm).

    Hypersensitivity to this product.

    Thiabendazole is contraindicated as prophylactic treatment for pinworm infestation.

    Gastrointestinal: anorexia, nausea, vomiting, diarrhea, epigastric distress, abdominal pain, jaundice, cholestasis, parenchymal liver damage and hepatic failure. 

    Central Nervous System: dizziness, weariness, drowsiness, giddiness, headache, numbness, hyperirritability, convulsions, collapse, confusion, depression, floating sensation, weakness and lack of coordination.

    Special Senses: tinnitus, abnormal sensation in eyes, xanthopsia, blurred vision, reduced vision, drying of mucous membranes (mouth, eyes, etc.), Sicca syndrome. 

    Cardiovascular: hypotension.

    Metabolic: hyperglycemia.

    Hematologic: transient leukopenia.

    Genitourinary: hematuria, enuresis, malodor of the urine, crystalluria.

    Hypersensitivity: pruritus, fever, facial flush, chills, conjunctival injection, angioedema, anaphylaxis, skin rashes (including perianal), erythema multiforme (including Stevens-Johnson syndrome), and lymphadenopathy.

    Miscellaneous: appearance of live Ascaris in the mouth and nose.

    If hypersensitivity reactions occur, the drug should be discontinued immediately and not be resumed. Erythema multiforme has been associated with thiabendazole therapy; in severe cases (Stevens-Johnson syndrome), fatalities have occurred.

    Because CNS side effects may occur quite frequently, activities requiring mental alertness should be avoided.

    Jaundice, cholestasis, and parenchymal liver damage have been reported in patients treated with MINTEZOL (thiabendazole) . In rare cases, liver damage has been severe and has led to irreversible hepatic failure.

    Pregnancy Category C: Reproduction and teratogenic studies done in the rabbit at a dose up to 15 times the usual human dose, in the rat at a dose equivalent to the human dose, and in the mouse at a dose up to 2% times the usual human dose, revealed no evidence of harm to the fetus.

    The recommended maximum daily dose of MINTEZOL (thiabendazole) is 3 grams.

    MINTEZOL (thiabendazole) should be given after meals if possible. Tablets MINTEZOL (thiabendazole) should be chewed before swallowing. Dietary restriction, complementary medications and cleansing enemas are not needed.

    The usual dosage schedule for all conditions is two doses per day. The dosage is determined by the patient’s weight.

    MINTEZOL (thiabendazole) Suspension, 500 mg per 5 mL, is white to off-white and is supplied as follows:

     in bottles of 120 mL
    ( 0.5 g/5 mL, 120 mL).